Peptide library
Your guide to this compound.
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. Approximately 48 minutes in healthy individuals after subcutaneous administration, per Symlin labeling. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Selected patients with type 1 or type 2 diabetes using mealtime insulin, according to the product label.
The labeled use concerns glucose management, not a general peptide weight-loss regimen.
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
Amylin-receptor activity complements insulin effects on post-meal glucose.
Amylin-receptor activity complements insulin effects on post-meal glucose. Insulin co-treatment creates important hypoglycemia risk. Initiation and insulin adjustment require the full prescribing instructions.
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Named U.S. product only; label revision 20191218. Educational extraction, not complete clinical review.
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
SYMLIN: serious product hypersensitivity, hypoglycemia unawareness, or confirmed gastroparesis. The boxed severe-hypoglycemia warning with insulin remains central to patient selection and monitoring.
Named U.S. product only; label revision 20191218. Educational extraction, not complete clinical review.
SYMLIN pen-injectors: refrigerate unused pens at 2–8°C and protect from light; never freeze. After first use, refrigerate or keep at ≤30°C and discard after 30 days, regardless of refrigeration. Do not exceed the printed expiry.
Named U.S. product only; label revision 20191218. Educational extraction, not complete clinical review.
SYMLIN is supplied as a solution in pen-injectors. Do not mix with insulin in the same syringe; injections must be separate. Oral medicines needing rapid or threshold exposure have label-specific timing requirements.
Named U.S. product only; label revision 20191218. Educational extraction, not complete clinical review.
Severe hypoglycemia can occur with insulin; nausea is also reported. Delayed gastric emptying can affect oral medicines. The label separates critical oral medicines by at least one hour before or two hours after SYMLIN.
Named U.S. product only; label revision 20191218. Educational extraction, not complete clinical review.
Primary source · Pramlintide
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.